The ascendancy of Viagra and its influence on the pharmaceutical landscape presents a complex question for traders. While the first sales data were astounding, the intellectual property has expired, leading to a flood of copycat alternatives that are eroding revenue. In addition, the industry is facing difficulties related to population trends and